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Leptin and insulin use overlapping signaling mechanisms to modify hepatic glucose metabolism, which
is critical in maintaining normal glycemia. We examined the effect of an increase in central leptin and
insulin on hepatic glucose metabolism and its influence on serum glucose levels. Chronic leptin infusion
increased serum leptin and reduced hepatic SH-phosphotyrosine phosphatase 1, the association of
suppressor of cytokine signaling 3 to the insulin receptor in liver and the rise in glycemia induced by
central insulin. Leptin also decreased hepatic phosphoenolpyruvate carboxykinase levels and increased
insulin's ability to phosphorylate insulin receptor substrate-1, Akt and glycogen synthase kinase on Ser9
and to stimulate glucose transporter 2 and glycogen levels. Peripheral leptin treatment reproduced some
of these changes, but to a lesser extent. Our data indicate that leptin increases the hepatic response to a
rise in insulin, suggesting that pharmacological manipulation of leptin targets may be of interest for
controlling glycemia.
© 2015 Elsevier Ireland Ltd. All rights reserved.1. Introduction
The liver is a key regulator of glucose homeostasis due to its
ability to store glucose as glycogen and to release it according to
peripheral demands (Jiao et al., 2013). Under physiological condi-
tions insulin regulates these fluxes by modifying transport into theormone; Akt, protein kinase
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tensity; OB-Rb, long form of
ykinase; PI3K, phosphatidyli-
10, catalytic subunit of PI3K;
S3, suppressor of cytokine
transcription factor 3.
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rved.hepatocyte and suppressing the expression of genes involved in
gluconeogenesis. Leptin also participates in the control of glycemia,
promoting glucose uptake and glycogen storage through stimula-
tion of phosphatidylinositol (PI)-3 kinase in the liver (Kellerer et al.,
1997).
Leptin and insulin regulate glycemia by acting on both central
and peripheral tissues and share several signaling targets in this
process (Li et al., 2011; D'Souza et al., 2014; Crepin et al., 2014).
Leptin acting centrally modulates peripheral insulin signaling
through several mechanisms, including changes in peripheral
hormones that affect insulin sensitivity and glucose metabolism
(Hidaka et al., 2002; Cettour-Rose et al., 2005; Bartell et al., 2011). In
liver, insulin-dependent glucoregulatory mechanisms are modu-
lated by phosphatases and kinases that regulate intracellular tar-
gets and their interactions. Indeed, association of insulin receptor
(IR) with suppressor of cytokine signaling 3 (SOCS3) and SH-
phosphotyrosine phosphatase 1 (SH-PTP1) are determining fac-
tors in hepatic glucoregulation (Oriente et al., 2011). The
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tions of leptin and insulin are more evident in obesity, as in most
instances these subjects exhibit insulin resistance related to an
increase in proinflammatory cytokines that aggravate this patho-
logical situation (Dali-Youcef et al., 2013). Although the contribu-
tion of adipose tissue to obesity related inflammation has been
reported (Kulyte et al., 2014), the role of the liver in the generation
of a pro- or anti-inflammatory profile remains unclear.
The effect of exogenous leptin on insulin's actions andmetabolic
outputs in peripheral tissues has been analyzed in models of
obesity and diabetes (Roman et al., 2010). However, there is little
information regarding the effects of an increase in central leptin
and insulin bioavailability on hepatic insulin sensitivity and its
relationship with interleukin levels and carbohydrate metabolism
in non-obese animals. Leptin decreases food intake and could
modify insulin sensitivity and hepatic glucose metabolism; hence it
would be important to discriminate the direct effects of leptin from
those due to decreased food intake (de Vries et al., 2014). Therefore,
we asked whether chronic central leptin infusion could improve
hepatic insulin signaling and glycemia in response to an insulin
bolus in a non-obese experimental model and the possible
involvement of systemic changes in this response. To discriminate
between the direct effects of leptin and those due only to a
reduction in food intake, a group of pair-fed rats were included.
2. Material and methods
2.1. Animals
This study was approved by the Ethics Committee of the Uni-
versidad de Alcala de Henares (SAF 22277, Ministerio de Ciencia y
Tecnología) and complied with Royal Decree 53/2013 pertaining to
the protection of experimental animals and with the European
Communities Council Directive (2010/63/EU).
2.1.1. Central leptin and insulin infusion
Thirty-six adult male Wistar rats (250 ± 10 g) were individually
cagedwith a 12-h light/dark cycle and fed standard chow andwater
ad libitum. After an overnight fast, rats were anesthetized (4 mg of
ketamine/100 g bw and 0.5 mg of xylazine/100 g bw) and posi-
tioned in a stereotaxic apparatus. A cannula attached to an osmotic
minipump (Alzet, Durect Corporation, Cupertino, CA) containing
either saline or leptin (Preprotech, Rocky Hill, NJ, USA; 12 mg/day
with a delivery volume of 0.5 ml/h) with 1% BSAwas implanted into
the right cerebral ventricle (0.3 mm anteroposterior, 1.1 mm
lateral from Bregma) and maintained during 14 days, and another
cannula linked to a catheter in the rat left lateral cerebral ventricle
where insulin was injected. Previously, in order to verify the ste-
reotactic coordinates, three male rats received an icv injection of
7 ml 0.4% Trypan Blue solution (SigmaeAldrich, St. Louis, MO, USA)
and were killed 2 h later (Miller et al., 2006). To discriminate the
inhibitory effect of leptin on appetite, a pair-fed group was
included. Food intake and body weight were measured daily. On
the last day, including a fasting period of 12 h, 10 mU of insulin
(Novo Nordisk Pharma, Madrid, Spain) in 7 ml PBS or PBS was
injected icv and the rats sacrificed by decapitation 2 h later. Gly-
cemia was measured before and 2 h after PBS or insulin adminis-
tration (Accu-Check Sensor, Roche, Mannheim, Germany). This
resulted in the following groups (n ¼ 6 per group): chronic vehicle
plus acute vehicle (control), chronic vehicle plus insulin (insulin),
pair-fed group with chronic vehicle and acute vehicle (pair-fed),
pair-fed groupwith chronic vehicle plus acute insulin (pair-fed plus
insulin), chronic leptin plus acute vehicle (leptin) and chronic leptin
plus acute insulin (leptin plus insulin).
A dose of leptin that might be considered supra-physiologicalwas chosen for this study as it is known to exert an effect on food
intake (Friedman and Halaas, 1998; Banks and Lebel, 2002). With
respect to insulin, brain levels are 10e100 times higher than in
blood and studies using higher icv insulin doses have been
considered to be in the physiological range (Tanaka et al., 2000).
Therefore, the dose employed in this study could be considered to
be in the physiological range and compatible with variations be-
tween fed and fasting states (Havrankova et al., 1978). A two-hour
post-insulin injection interval was chosen because at one hour
differences in activation of some signaling targets were observed,
but not in parameters related to metabolism. At longer time-
periods changes in the activation of many signaling targets were
no longer detectable.
2.1.2. Oral glucose tolerance test
To determine how chronic central leptin infusion affects glucose
metabolism, an oral glucose tolerance test (OGTT) was performed
in control, pair-fed and central leptin-treated rats (n¼ 4 per group).
After 14 days of central saline or leptin (12 mg/day) infusion and a
fasting period of 12 h, glucose (2 g/kg body weight) dissolved in
water was administered orally using gavage tubes (Suresha et al.,
2013). Blood samples were extracted from the tail vein before
administration of a glucose bolus and at 15, 30, 60, 120 and 180 min
for determination of glucose levels (Accu-Check Sensor).
2.1.3. Intraperitoneal insulin tolerance test
Insulin sensitivity was assessed after overnight fasting by per-
forming an intraperitoneal insulin tolerance test (IPITT) in control,
pair-fed and central leptin-treated rats (n ¼ 4 per group). After the
injection of a bolus of 2 U/kg of insulin, blood samples were drawn
consecutively at 15, 30, 60, 90, 120 and 180 min for glucose mea-
surement (Ndisang et al., 2010), as described above.
2.1.4. Peripheral leptin and central insulin administration
Sixteen adult maleWistar rats (250 ± 10 g) were anesthetized as
stated above and received either saline (n ¼ 8) or leptin (n ¼ 8,
0.2 mg/kg/day) via a subcutaneously implanted Alzet osmotic
minipump (Scarpace et al., 2000). After 14 days,10 mU of insulin (in
7 ml PBS) or PBS alone was injected icv and the rats sacrificed by
decapitation 2 h later. This resulted in the following groups (n ¼ 4
per group): chronic peripheral vehicle plus acute central vehicle
(control), chronic peripheral vehicle plus acute central insulin (in-
sulin), chronic peripheral leptin plus acute central vehicle (leptin)
and chronic peripheral leptin plus acute central insulin (leptin plus
insulin).
2.2. Hormone measurements
Serum leptin and insulin concentrations were determined using
ELISA kits from Millipore Corporate Headquarters (Billerica, MA,
USA). Serum glucagon and acylated and total ghrelin were
measured by using RIA kits from Millipore. Serum a-melanocyte
stimulating hormone (a-MSH) levels were evaluated by an ELISA kit
from Cusabio (Wuhan, China). The intra- and inter-assay variations
were lower than 10% in all cases.
2.3. Immunoprecipitation
The associations between targets were studied by immuno-
precipitation. Thirty mg of liver were homogenized on ice in 500 ml
of lysis buffer pH 7.6 containing 50 mmol/l HEPES, 10 mM EDTA,
50 mmol/l sodium pyrophosphate, 100 mmol/l NaF, 10 mmol/l
Na3VO4, 1% Triton X-100, 2 mmol/lphenylmethylsulfonyl fluoride,
10 mg/ml leupeptin and 10 mg/ml aprotinin. Before immunopre-
cipitation, liver homogenates were centrifuged twice at 12,000 g
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night at 4 Cwith the corresponding antibodies and incubated with
protein A-agarose beads for 2 h at 4 C. Immunocomplexes were
washed with lysis buffer, extracted for 5 min at 95 C in 2X SDS-
PAGE sample buffer (200 mmol/lTris-HCl, 10% SDS, 0.01 M bromo-
phenol blue, 8% 2-mercaptoethanol, 20% glycerol, pH 7.6) and
analyzed by Western blotting as described below.
2.4. Western blotting
Western blots for immunocomplexes and hepatic homogenates
were performed using antibodies against phosphorylated (p)
Tyr705-signal transducer and activator of transcription factor 3
(pTyr705-STAT3), pSer727-STAT3 and SOCS3 from Cell Signaling
Technology (Danvers, MA), pTyr1007/1008 Janus kinase 2 (pJAK2),
JAK2 and regulatory subunit of PI3K (p85) from Millipore (Teme-
cula, CA), STAT3 from R&D Systems (Minneapolis, MN) and
aquaglyceroporin-9 (AQP9), the beta chain of insulin receptor (IRb),
catalytic subunit of PI3K (p110), GLUT2, long form of the leptin
receptor (OBeRb), phosphoenolpyruvate carboxykinase (PEPCK)
and SH-PTP1 from Santa Cruz Biotechnology (Santa Cruz, CA). The
proteins were detected by chemiluminiscence using an ECL system.
Quantification of the bands was carried out by densitometry using a
Kodak Gel Logic 1500 Image Analysis system and Molecular Im-
aging software 4.0 (Rochester, NY, USA). AQP9, GLUT2, IRb, OB-Rb,
p85, PEPCK, SOCS3 and SH-PTP1 were normalized with actin
(Thermo Scientific, Fremont, CA), whereas pJAK2, pTyr705-STAT3
and p-Ser727- STAT3 were normalized with their respective total
forms.
2.5. Multiplexed bead immunoassay
Phosphorylated and total levels of glycogen synthase kinase-3b
(GSK3b), insulin receptor substrate 1 (IRS1), Akt and c-Jun N-ter-
minal kinase (JNK) and serum and hepatic IL-2, IL-4, IL-6 and IL-10
were determined by multiplexed bead immunoassays (Bio-Rad
Laboratories, Madrid, Spain and Millipore; respectively), following
the manufacturer's recommendations. A minimum of 50 beads per
parameter were analyzed in the Bio-Plex suspension array system
200 (Bio-Rad). Raw data (median fluorescence intensity, MFI) were
analyzed with the Bio-Plex Manager Software 4.1 (Bio-Rad
Laboratories).
2.6. Measurement of hepatic glucose and glycogen
Liver samples (1 g) were incubated with 2 ml potassium hy-
droxide 30% at 100 C for 15 min. The tissue debris was removed by
centrifugation at 2000 g for 5 min, the supernatants precipitated
with 200 ml sodium sulfate plus 4ml ethanol and then cooled on ice
for 15 min. Glycogen pellets were obtained by centrifugation at
2000 g for 5 min and hydrolyzed with 1 ml sulfuric acid 5N and
boiled for 45 min. The samples were neutralized and glucose con-
centration determined by an enzymatic method from Sigma-
eAldrich (GAGO-20).
2.7. Immunohistochemistry and nuclear staining
Fluorescent immunohistochemistry was performed on frozen
10 mmcryostat sections that were fixed in 4% paraformaldehyde (w/
v) for 20 min, washed, blocked with PBS containing 3% BSA and 1%
Triton X-100 for 90 min and incubated 48 h at 4 C with anti-Akt
(1:300, Santa Cruz Biotechnology) with blocking buffer. Sections
were washed and incubated for 120 min at RT with anti-goat IgG
biotin (1:1000, Thermo Scientific) with blocking buffer. Afterwards,
sections were washed and incubated under dark conditions withstreptavidin Alexa Fluor 488 (1:2000, Molecular Probes, Leiden, The
Netherlands) in blocking buffer for 120 min at RT and washed three
times with PBS containing 0.1% BSA and 0.1% Triton X-100. Sections
were incubated for 5 min at RT with DRAQ5 (1:5000, BioStatus Ltd.,
Leics, United Kingdom) in PBS, mounted and cover-slipped with
Clear Mount (Electronic Microscopy Sciences, Hatfield, PA).
Immunofluorescence was visualized with a DM IRB confocal mi-
croscope (Leica, Wetzlar, Germany).
2.8. RNA purification and real time PCR analysis
Total RNAwas extracted from 50 mg of inguinal fat according to
the Tri-Reagent protocol (Sigma, St. Louis, USA). Reverse tran-
scription was performed on 2 mg of total RNA using a high-capacity
cDNA kit (Applied Biosystems). Real-time PCR was performed in an
ABI Prism 7000 Sequence Detection System (Applied Biosystems)
using TaqMan PCR Master Mix (Applied Biosystems) and the ther-
mocycler parameters recommended by the manufacturer. PCRs
were performed in duplicate in a total volume of 50 ml, containing
25 ml of the reverse transcription reaction. TaqMan gene expression
assay were used for analyzing the gene expression of leptin
(Rn00565158_m1, Applied Biosystems) following the manufac-
turer's procedures. Relative gene expression comparison was
carried-out using an invariant endogenous control (actin,
Rn00667869_m1, Applied Biosystems). According to the manufac-
turer's guidelines, the DDCT method was used for relative
quantification.
2.9. Statistical analysis
Data are presented as mean ± SEM. Statistical comparison to
assess a possible interaction between leptin and insulin infusion
was performed by two-way ANOVA. Statistical analysis of all data
was carried out by one-way ANOVA followed by a Bonferroni's test.
Pearson's correlation coefficient r was used to measure the degree
of association between different variables in each group. Values
were considered significantly different when the P value was less
than 0.05. Statistical analyses were conducted with Prisma soft-
ware 4.00 (GraphPad, San Diego, CA, USA) with an a level of 0.05.
3. Results
3.1. General characteristics of experimental groups
Average daily food intake was reduced in the pair-fed, pair-fed
plus insulin, leptin and leptin plus insulin groups (Fig. 1A). Body
weight gainwas lower in the same groups, with amore pronounced
reduction in both leptin groups (Fig. 1B). Leptin- and leptin plus
insulin-treated rats had less subcutaneous (control: 4.35 ± 0.19,
control plus insulin: 4.17 ± 0.28, pair-fed: 3.12 ± 0.32, pair-fed plus
insulin: 3.05 ± 0.16, leptin: 1.98 ± 0.15 and leptin plus insulin:
2.13 ± 0.20 g) and epididymal fat pads (control: 3.72 ± 0.25, control
plus insulin: 4.03 ± 0.38, pair-fed: 2.80 ± 0.47, pair-fed plus insulin:
2.65 ± 0.10, leptin: 1.64 ± 0.15 and leptin plus insulin: 1.49 ± 0.26 g)
compared with their respective control or pair-fed groups (p < 0.01
for both).
Serum acylated ghrelin was increased in pair-fed and leptin-
treated rats and rose after insulin treatment with an interaction
between leptin and insulin (F: 9.09, p < 0.001), as the insulin
induced rise was smaller in the leptin group (Fig. 1C). Total ghrelin
levels did not change (data not shown) and glucagon levels were
reduced in the pair-fed and leptin-treated groups (Fig. 1D). Serum
insulin concentrations were unaffected by leptin or insulin treat-
ments (Fig. 1E). Insulin infusion augmented serum a-MSH levels in
pair-fed and leptin-treated rats, with this rise being greater in
Fig. 1. General characteristics of the experimental groups. C, control rats; CI, rats receiving acute central administration of insulin; PF, pair-fed rats; PFI, pair-fed rats treated with
insulin; L, rats treated with chronic icv leptin infusion and LI, rats treated with leptin plus insulin. (A) Daily food intake. (B) Increase in body weight. (C) Serum acylated ghrelin
concentrations. (D) Serum glucagon concentrations. (E) Serum insulin concentrations. (F) Serum a-melanocyte stimulating hormone (a-MSH) concentrations. (G) Serum leptin
concentrations. (H) Relative mRNA levels of leptin in inguinal fat. Data are presented as means ± SEM. N ¼ 6. For the clarity of the panels A and B, pair-fed and leptin groups with or
without the subsequent insulin treatment have been combined, due to the lack of differences in these parameters. Different symbols refer to significant differences between groups,
“*” different from C, “#” from CI, “&” from PF, “o” from PFI and “$” from L. Significance: p < 0.05 in panels A and D; p < 0.01 in panels B, C, F and H and p < 0.001 in panel G.
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insulin (F: 17.26, p < 0.001).
3.2. Chronic central leptin infusion increases serum leptin and
leptin gene expression
Serum leptin concentrations were increased in the leptin and
leptin plus insulin groups (Fig. 1G). To analyze if adipose tissue
contributes to this rise, mRNA levels of leptin were analyzed in
subcutaneous and visceral adipose pads. Relative leptin mRNA
levels were increased in inguinal fat of the leptin and leptin plusinsulin groups (Fig.1H), with no changes in epididymal fat (data not
shown).
3.3. Leptin reduces the rise in glycemia induced by central insulin
and lowers serum glucose levels after oral glucose or intraperitoneal
insulin administration
Blood glucose levels were in the normal range in all groups,
including before insulin administration. However, chronic exposure
to increased central leptin attenuated the rise in glycemia induced
by central insulin administration (Fig. 2A, interaction leptin and
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Oral administration of glucose triggered an increase in glycemia
in all groups, with this rise being lower in the pair-fed and leptin
groups with respect to controls and in leptin-treated rats comparedFig. 2. Serum glucose levels after central insulin infusion, oral glucose tolerance test
(OGTT) or intraperitoneal insulin tolerance test (IPITT). (A) Serum glucose levels after
central insulin infusion. C, control rats; CI, rats receiving acute central administration
of insulin; PF, pair-fed rats; PFI, pair-fed rats treated with insulin; L, rats treated with
chronic icv leptin infusion and LI, rats treated with leptin plus insulin. (B) Serum
glucose levels before (0 min) and during (15, 30, 60, 90, 120 and 180 min) an OGTT.
C þ G, control rats that received oral glucose; PF þ G, pair-fed rats that received oral
glucose; L þ G, rats treated with chronic icv leptin infusion that received oral glucose.
(C) Serum glucose levels before (0 min) and during (15, 30, 60, 90, 120 and 180 min) an
IPITT. C þ I, control rats that received an IP insulin bolus; PF þ I, pair-fed rats that
received an IP insulin bolus; L þ I, rats treated with chronic icv leptin infusion that
received an IP insulin bolus. Data are presented as means ± SEM. N ¼ 4. Different
symbols refer to significant differences between groups or time-period, “*” different
from C þ G or C þ I, “#” from PF þ G or PF þ I and “&” statistical difference vs. previous
point. Significance: p < 0.05.to the pair-fed group (Fig. 2B). Intraperitoneal (IP) insulin admin-
istration provoked a rapid drop in glycemia in all groups, with this
decline being more pronounced in leptin-treated rats at 60 and
90 min (Fig. 2C).3.4. Central administration of leptin and insulin modifies their
signaling pathways in the hypothalamus
Phosphorylation of STAT3 on Tyr705 was diminished by pair-
feeding, with insulin stimulating phosphorylation of this protein
only in the leptin-treated group (Fig. 3A). Levels of p110 were
increased in leptin treated rats with no effect of insulin in any group
(Fig. 3B). Activation of Akt was reduced in pair-fed and augmented
in leptin-treated rats, with insulin increasing the degree ofFig. 3. Leptin infusion activates the PI3K pathway in the hypothalamus. C, control rats;
CI, rats receiving acute central administration of insulin; PF, pair-fed rats; PFI, pair-fed
rats treated with insulin; L, rats treated with chronic icv leptin infusion and LI, rats
treated with leptin plus insulin. (A) Relative signal transducer and activator of tran-
scription 3 (STAT3) phosphorylated on Tyr705 (p-Tyr705-STAT3) protein levels. (B)
Relative levels of catalytic subunit of PI3K (p110) protein levels. (C) Relative phos-
phorylated (p) Akt on serine 473 (pSer473Akt) protein levels. Data are presented as
means ± SEM. N ¼ 6. DU, densitometry units; MFI, median fluorescent intensity.
Different symbols refer to significant differences between groups, “*” different from C,
“#” from CI, “&” from PF, “o” from PFI and “$” from L. Significance: p < 0.05 in panel A;
p < 0.01 in panel C and p < 0.001 in panel B.
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(Fig. 3C).
3.5. The effect of central insulin on hepatic leptin signaling
pathways is modulated by central leptin infusion
There were no differences in OB-Rb protein levels (Fig. 4A).
Phosphorylation of JAK2 decreased in response to insulin in control
and pair-fed rats and, although leptin alone had no effect, it abol-
ished this response to insulin (Fig. 4B). Phosphorylation of STAT3 on
Tyr705 was diminished in pair-fed and leptin-treated rats with no
effect of insulin (Fig. 4C) and pSer727-STAT3 levels were lower in
leptin treated rats, with a reduction after insulin treatment in pair-
fed rats (Fig. 4D). No differences in total STAT3 levels (control:
100.0 ± 7.2, control plus insulin: 85.6 ± 9.2, pair-fed: 97.2 ± 5.4,
pair-fed plus insulin: 81.7 ± 8.9, leptin: 103.6 ± 7.0 and leptin plusFig. 4. Central insulin modulates hepatic leptin signaling. C, control rats; CI, rats receiving
insulin; L, rats treated with chronic icv leptin infusion and LI, rats treated with leptin plus in
liver. (B) Relative phosphorylated (p) Janus kinase 2 (JAK2) protein levels. (C) Relative sign
Tyr705-STAT3) protein levels. (D) Relative STAT3 phosphorylated on Ser727 (p-Ser727-STAT
(F) Relative levels of SOCS3 associated with OB-Rb. Data are presented as means ± SEM. N ¼
Different symbols refer to significant differences between groups, “*” different from C, “#”insulin: 87.6 ± 8.0, expressed as the percentage of densitometry
units in the control) were found. Levels of SOCS3 were unchanged
after leptin, with an interaction between treatments (F ¼ 4.45,
p < 0.05), as leptin reduced the stimulatory effect of insulin on
SOCS3 (Fig. 4E). There was an effect of leptin treatment and insulin,
with an interaction of these factors (F ¼ 3.72, p < 0.05), on
SOCS3eOBRb association (Fig. 4F). Association of SOCS3eOBRbwas
increased in pair-fed rats, with insulin decreasing this association in
pair-fed and leptin-treated rats. Together these data suggest that
leptin changes the ability of insulin to modulate hepatic leptin
signaling.
3.6. Leptin activates the IRS1/PI3K pathway and translocation of
Akt to the nucleus
There was no change in hepatic IR levels (Fig. 5A), but leptinacute central administration of insulin; PF, pair-fed rats; PFI, pair-fed rats treated with
sulin. (A) Relative protein levels of the long form of the leptin receptor (OBeRb) in the
al transducer and activator of transcription 3 (STAT3) phosphorylated on Tyr705 (p-
3) protein levels. (E) Relative suppressor of cytokine signaling 3 (SOCS3) protein levels.
6. The data are expressed as a percentage of the control ratio. DU, densitometry units.
from CI, “&” from PF, “o” from PFI and “$” from L. Significance: p < 0.01 in all panels.
Fig. 5. Leptin activates IRS1/PI3K pathway in the liver. C, control rats; CI, rats receiving acute central administration of insulin; PF, pair-fed rats; PFI, pair-fed rats treated with
insulin; L, rats treated with chronic icv leptin infusion and LI, rats treated with leptin plus insulin. (A) Relative protein levels of the insulin receptor beta chain (IRb) in the liver. (B)
Relative levels of suppressor of cytokine signaling 3 (SOCS3) associated with IRb. (C) Relative levels of IRS1. (D) Relative levels of IRS1 associated to IRb. (E) Relative phosphorylated
(p) IRS1 protein levels. (F) Relative levels of Janus kinase 2 (JAK2) bound to IRS1. (G) Relative levels of regulatory subunit of PI3K (p85) bound to IRS1. Data are presented as
means ± SEM. N ¼ 6. DU, densitometry units; MFI, median fluorescent intensity. Different symbols refer to significant differences between groups, “*” different from C, “#” from CI,
“&” from PF, “o” from PFI and “$” from L. Significance: p < 0.05 in panels B, D and E and p < 0.01 in panel C.
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(F ¼ 4.18, p < 0.05). Association of SOCS3 to IRb was increased in
pair-fed rats and in controls after insulin treatment (Fig. 5B). Total
IRS1 was increased by leptin, with no influence of insulin (Fig. 5C).The association of IRS1 to IRb was increased in pair-fed and leptin-
treated rats, with insulin having a stimulatory effect only in con-
trols (Fig. 5D). Leptin augmented IRS1 phosphorylation, with a
positive effect of insulin in the control and leptin groups (Fig. 5E,
E. Burgos-Ramos et al. / Molecular and Cellular Endocrinology 415 (2015) 157e172164interaction treatment and insulin: F ¼ 7.24, p < 0.01).
Association of IRS1 to JAK2 was diminished in pair-fed rats, with
no effect of insulin (Fig. 5F). Leptin did not change IRS1-p85 asso-
ciation; however, insulin increased it in control and leptin-treated
rats, but not in pair-fed rats (Fig. 5G). Linear regression analyses
showed correlations between IRb-IRS1 and IRS1-JAK2 (r ¼ 0.58,
p < 0.01) and between IRS1-JAK2 and IRS1-p85 (r ¼ 0.45, p < 0.05).
Leptin augmented Akt phosphorylation, with insulin increasing
pAkt in all groups and having a greater effect in leptin-treated rats
(Fig. 6A). Immunolocalization studies showed that after insulin
infusion, Akt was preferentially located in the cytoplasm in control
and pair-fed groups, whereas in leptin-treated rats was also
detected in the nucleus (Fig. 6B to J).
3.7. Activation of the IRS1/PI3K pathway is related to a reduction in
JNK phosphorylation and SH-PTP1 levels
Phosphorylation of JNK and SH-PTP1 levels is negatively regu-
lated by insulin in control rats (Fig. 6K and L, respectively). Leptin
also decreased JNK phosphorylation and SH-PTP1 levels, with in-
sulin having no effect in leptin-treated rats. Insulin decreased pJNK
and SH-PTP1 in pair-fed rats, with this decline being significant
only in the latter.
3.8. Chronic leptin exposure modifies levels and association of
targets related to hepatic insulin sensitivity
No change in serum IL-6 or IL-10 levels was found (Fig. 7A and B,
respectively). There was an interaction between treatment and
insulin on serum IL-2 levels (F ¼ 5.70, p < 0.01). IL-2 was
augmented in leptin-treated rats and insulin increased it in control
and pair-fed and reduced it in leptin-treated rats (Fig. 7C). Serum IL-
4 was increased in leptin and leptin plus insulin-treated rats
(Fig. 7D).
The hepatic content of IL-6 was augmented in pair-fed and
leptin-treated rats, with an increase after insulin in the pair-fed
group (Fig. 7E), with an interaction between treatment and insu-
lin (F: 6.12, p < 0.01). Leptin had no effect on IL-10 levels, but
blocked the insulin induced rise seen in the control and pair-fed
groups (Fig. 7F). Liver IL-2 levels were increased in the pair-fed
group and diminished in leptin-treated rats (Fig. 7G). Hepatic IL-4
content augmented after leptin infusion and insulin increased it
in pair-fed and leptin-treated rats (Fig. 7H).
3.9. Leptin increases GLUT2 and reduces PEPCK levels in the liver
To test the possible role of the liver in the changes observed in
glycemia, we analyzed serum glycerol levels, which were increased
in pair-fed rats (Fig. 8A). In addition, levels of GLUT2 were
measured. Leptin augmented hepatic GLUT2 and insulin treatment
increased it only in controls (Fig. 8B). Leptin diminished PEPCK
levels, with insulin having an inhibitory effect in controls (Fig. 8C,
interaction treatment and insulin: F ¼ 3.95, p < 0.05). Hepatic
AQP9, which captures glycerol for gluconeogenesis (Rodríguez
et al., 2011), was reduced in leptin-treated rats (Fig. 8D).
3.10. Central insulin effects on glycogen synthesis are potentiated
by leptin
Total GSK3b levels were decreased in leptin-treated rats (Fig. 8E).
Leptin increased GSK3b phosphorylation on serine 9 with a stimu-
latory effect of insulin in this group (Fig. 8F, interaction treatment
and insulin: F ¼ 246.96, p < 0.001). Hepatic glycogen content was
reduced in pair-fed rats and insulin increased glycogen only in
leptin-treated rats (Fig. 8G, interaction: F ¼ 19.24, p < 0.001).3.11. Effect of peripheral leptin on food intake, body weight, serum
hormone levels and hepatic insulin signaling
Average daily food intake was reduced after peripheral leptin
administration (Fig. 9A). Body weight gain at the end of study was
also lower (Fig. 9B). Serum leptin was augmented in the leptin and
leptin plus insulin groups (Fig. 9C) and glucagon levels were un-
changed in the leptin-treated groups (Fig. 9D). Serum insulin levels
were unchanged (data not shown). Insulin infusion increased
serum a-MSH levels in leptin-treated rats (Fig. 9E).
When hepatic insulin signaling was analyzed, insulin increased
phosphorylation of IRS1 in leptin-treated rats (Fig. 9F). Akt activa-
tion was not affected by leptin treatment, with insulin increasing
pAkt levels in both control and leptin-treated rats, with no differ-
ences between them (Fig 9G). Finally, leptin did not modify hepatic
glycogen levels, but insulin increased glycogen only in leptin-
treated rats (Fig. 9H, interaction leptin and insulin: F ¼ 5.87,
p < 0.01).
3.12. Comparison of central vs. peripheral effects
We compared the percentage of variation in key parameters
after central or peripheral leptin administration, as well as the
degree of insulin response in both groups of leptin-treated rats. The
increase in body weight at the end of the study in respect to their
controls was higher in peripheral- (19.6%) than in central-treated
rats (5.7%, p < 0.001).
Serum leptin levels were similar in both groups of leptin-treated
rats (Fig. 1G and 9C), however; glucagon levels in peripheral
treatment groups remained unchanged (Fig. 9D), whereas central
leptin reduced these levels (Fig. 1D). Serum a-MSH showed no
differences between after central or peripheral leptin administra-
tion, nevertheless; the increment in serum levels after insulin
infusion was lower in peripheral leptin group (62%) than in rats
centrally treated (173%, p < 0.01).
When we analyzed insulin signaling in the liver, peripheral
leptin did not modify activation of IRS1, however; central leptin
increased it. The activation of this target after insulin infusion was
lower in peripheral leptin-treated rats (18%) than after central
leptin infusion (37%, p < 0.01). Phosphorylation of Akt did not
change in response to peripheral leptin-treatment and its augment
after insulin infusion was lower (16%) than that observed in central
leptin-treated group (40%, p < 0.01). Finally, the increase in
glycogen content in the liver after insulin infusion was inferior in
peripheral leptin-treated rats (120%) than in those centrally treated
(485%, p < 0.001).
4. Discussion
Our results suggest that leptin reduces the rise in glycemia
induced by increased brain insulin levels by modifying hepatic
glucosemetabolism. The central insulin induced increase in hepatic
glycogen levels, is associatedwith the activation of insulin signaling
in the liver, even though circulating insulin levels are unchanged.
Modifications in serum acylated ghrelin, glucagon, leptin and
several interleukins could induce some of the observed changes in
hepatic metabolism and subsequent modifications in glycemia in
response to central insulin administration. Some of the effects on
hepatic insulin signaling in response to central leptin administra-
tion could be directly attributed to increased serum levels of leptin.
However, the changes observed with peripherally infused leptin,
reaching similar levels of hyperleptinemia, were not equivalent.
Peripherally infused leptin did not modify key hepatic targets that
were modified by central leptin infusion, such as pIRS1 and pAkt.
Furthermore, the effect of leptin on the response to central insulin
Fig. 6. Leptin increases Akt activation and its nuclear localization. C, control rats; CI, rats receiving acute central administration of insulin; PF, pair-fed rats; PFI, pair-fed rats treated
with insulin; L, rats treated with chronic icv leptin infusion and LI, rats treated with leptin plus insulin. (A) Relative phosphorylated (p) Akt on serine 473 (pSer473Akt) protein levels.
(BeJ) Immunohistochemistry of Akt (green) with nuclear staining (DRAQ5, red) in the liver of CI, PFI and LI, respectively. Note the colocalization in the merged images (G and J). Scale
bar, 40 mm. (K) Relative phosphorylated c-Jun N-terminal kinase (pJNK) protein levels. (L) Relative levels of the SH-phosphotyrosine phosphatase 1 (SH-PTP1). Data are presented as
means ± SEM. N ¼ 6. DU, densitometry units; MFI, median fluorescent intensity. Different symbols refer to significant differences between groups, “*” different from C, “#” from CI,
“&” from PF, “o” from PFI and “$” from L. Significance: p < 0.05 in panels A and K and p < 0.01 in panel L.
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part, to the fact that centrally injected leptin-animals displayed
more dramatic reductions in body weight and adipose tissue than
those peripherally infused.
Our findings show that leptin actions are involved in the regu-
lation of glycemia. Central insulin infusion increased serum glucoseand leptin reduced this induced rise in glycemia. Moreover, the
response in glucose and insulin tolerance tests also suggest that
central leptin improves insulin control of glucose levels, as sug-
gested previously (Park et al., 2008). Changes in peripheral hor-
mones after central leptin infusion could also be involved in
regulation of glycemia as a rise in central leptin is reported to
Fig. 7. Leptin modifies serum and hepatic levels of interleukins (ILs). C, control rats; CI, rats receiving acute central administration of insulin; PF, pair-fed rats; PFI, pair-fed rats
treated with insulin; L, rats treated with chronic icv leptin infusion and LI, rats treated with leptin plus insulin. (A) Serum IL-6 concentrations. (B) Serum IL-10 concentrations. (C)
Serum IL-2 concentrations. (D) Serum IL-4 concentrations. (E) Hepatic content of IL-6. (F) Hepatic content of IL-10. (G) Hepatic content of IL-2. (H) Hepatic content of IL-4. Data are
presented as means ± SEM. N ¼ 6. Different symbols refer to significant differences between groups, “*” different from C, “#” from CI, “&” from PF, “o” from PFI and “$” from L.
Significance: p < 0.05 in panels C, F and G; p < 0.01 in panels E and H and p < 0.001 in panel D.
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observed here appear to be independent of leptin-induced changes
in food intake as not only is the reduction in glycemia after insulin
different in pair-fed and leptin-treated rats, but also the changes in
hepatic signaling and glucose metabolism. Accordingly, leptin
infusion regulates glycemia independently of food intake (Hidaka
et al., 2002). Leptin-treated rats exhibited lower glucagon levels
that may be associatedwith the observed improvement in glycemia
control. Indeed, leptin has beneficial effects for treatment of dia-
betes (Wang et al., 2010) and these effects may be related toinhibition of glucagon (Lee et al., 2014). Finally, leptin infusion
provokes hyperleptinemia (Morrison et al., 2001) and although icv
leptin contributes to this rise (Maness et al., 1998), increased syn-
thesis in fat indicates that it is at least partially due to increased
production. Although the mechanism is not fully understood,
infusion of leptin into the brain promotes triiodothyronine pro-
duction (Cusin et al., 2000), which increases leptin mRNA levels in
fat (Ramsay and Richards, 2004). The increase in leptin expression
could be related to an increase in insulin sensitivity, as this hor-
mone augments leptin synthesis in fat (Saladin et al., 1995;
Fig. 8. Leptin and insulin modulate hepatic glucose metabolism. C, control rats; CI, rats receiving acute central administration of insulin; PF, pair-fed rats; PFI, pair-fed rats treated
with insulin; L, rats treated with chronic icv leptin infusion and LI, rats treated with leptin plus insulin. (A) Serum glycerol concentrations. (B) Relative protein levels of glucose
transporter (GLUT)2 in the liver. (C) Relative protein levels of phosphoenolpyruvate carboxykinase (PEPCK) in the liver. (D) Relative protein levels of aquaglyceroporin (AQP)9 in the
liver. (E) Relative protein levels of glycogen synthase kinase (GSK)3b in the liver. (F) Relative phosphorylated GSK3b on serine 9 (pSer9-GSK3b) protein levels in the liver. (G) Hepatic
glycogen concentrations. Data are presented as means ± SEM. N ¼ 6. DU, densitometry units; MFI, median fluorescent intensity. Different symbols refer to significant differences
between groups, “*” different from C, “#” from CI, “&” from PF, “o” from PFI and “$” from L. Significance: p < 0.05 in panels A and B; p < 0.001 in panels C, D, E, F and H and p < 0.001
in panel G.
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mRNA in adipose tissue (MacDougald et al., 1995). Central leptin
infusion has also been demonstrated to increase plasma cortico-
sterone (Van Dijk et al., 1997) that augments leptin in adipose tissue
(Fried et al., 2000).
Leptin and insulin activate their signaling pathways in thehypothalamus and increase circulating a-MSH levels. In fact, central
infusion of both hormones is reported to increase a-MSH and
reduce weight gain and adiposity (Dhillon et al., 2000) and muta-
tions that inactivate a-MSH degradation reduce hepatic PEPCK and
improve glucose homeostasis (Jeong et al., 2012). Moreover, a
reduction in a-MSH production is associated with increased
Fig. 9. Effects of peripheral leptin administration. PC, control rats; PCI, rats receiving acute central administration of insulin; PL, rats treated with chronic peripheral leptin
administration and PLI, rats treated with chronic peripheral leptin plus central insulin. (A) Mean daily food intake. (B) Increase in body weight at the end of the study. (C) Serum
leptin concentrations. (D) Serum glucagon concentrations. (E) Serum a-melanocyte stimulating hormone (a-MSH) concentrations. (F) Relative phosphorylated (p) IRS1 protein
levels. (G) Relative phosphorylated (p) Akt on serine 473 (pSer473Akt) protein levels. (H) Hepatic glycogen concentrations. Data are presented as means ± SEM. N ¼ 4. MFI, median
fluorescent intensity. Different symbols refer to significant differences between groups, “*” different from PC, “#” from PCI and “&” from PL. Significance: p < 0.05 in panels A, C, E, F
and G and p < 0.01 in panel B.
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our results suggest that activation of central signaling is related
with an improvement in the control of glycemia mediated by an
increase in circulating a-MSH levels.
Our findings suggest that hepatic activation of leptin and insulin
signaling pathways plays an important role in the control of gly-
cemia through augmenting utilization of glucose by the liver for
glycogen synthesis. We show that insulin was unable to induce
SOCS3 after leptin infusion and this resulted in reduced SOCS3
binding to IRb, allowing IRb to interact with IRS1, which wouldpotentiate insulin signaling (Zolotnik et al., 2012). We also found an
increase in pIRS1 levels with subsequent Akt activation. These data
suggest that reduction of SOCS3 may play a protective role against
insulin resistance and glucose intolerance (Huynh et al., 2010).
Lower JNK activation in leptin-treated rats might explain the rise in
IRS1 levels, as JNK degrades IRS1 and reduces hepatic insulin
signaling (Taniguchi et al., 2005), worsening glucose homeostasis.
The reduction in hepatic SH-PTP1 levels in leptin-treated rats could
also be related to improved control of serum glucose as SH-PTP1
prevents insulin-stimulated Akt activation through p85
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(Drapeau et al., 2013). Changes in hepatic insulin signaling after its
central infusion seem to be associated with variations in circulating
hormones, such as a-MSH (Jeong et al., 2012). Indeed, treatment
with melanocortin receptor agonists augments insulin sensitivity
in the liver (Kumar et al., 2009). In addition, the reduced rise in
ghrelin after central insulin infusion in leptin-treated rats could be
an additional factor that maintains insulin sensitivity (Longo et al.,
2011; Neuman et al., 2014). Additionally, it has been reported that
STAT3 activation in the hypothalamus plays a key role in glucose
homeostasis and insulin sensitivity in the liver (Wu et al., 2014) and
we have STAT3 phosphorylation to increase after insulin infusion in
leptin-treated rats.
Cumulating evidence indicates that a reduction in adiposity
enhances insulin sensitivity. In this regard, leptin decreases fat
mass and improves hepatic insulin action, inhibiting glucose syn-
thesis and augmenting its uptake (Barzilai et al., 1997). Moreover, in
models of type 2 diabetes with augmented adiposity, leptin reduces
fat stores, improving lipidmetabolism independently of food intake
with a concomitant enhancement of insulin sensitivity (Kusakabe
et al., 2009; Sakai et al., 2014). Inflammation is also associated
with insulin resistance. The lower adiposity found in leptin-treated
rats could also change systemic metabolic signals such as inter-
leukin levels, thus modifying insulin sensitivity (Beretta et al.,
2002; Cettour-Rose et al., 2005). Hepatic IL-2 was reduced after
leptin treatment, concordant with the relationship between lower
JNK activity and IL-2 levels and improved glycemia (Jiang et al.,
2013). Augmented IL-4 after leptin treatment may be a mecha-
nism by which Akt is activated, as IRS1 is phosphorylated by this
interleukin (Xiao et al., 2002). However, insulin resistance is asso-
ciated with adiposity, while weight loss enhances insulin sensi-
tivity with a simultaneous decrease in proinflammatory cytokines
(German et al., 2009). Endoplasmic reticulum (ER) stress is a po-
tential contributor to the development of insulin resistance and
hepatic inflammation (Brenner et al., 2013). Leptin inhibits ER
stress proteins (Xiong et al., 2014) and attenuation of ER stress
improves glucose homeostasis and insulin signaling in liver
(Latreille et al., 2011). In addition, an increase in ER stress is linked
to stimulation of gluconeogenesis (Wang et al., 2009). Our results
suggest that the decline in proinflammatory cytokines and the
reduction of PEPCK, improvement of insulin signaling and glycemia
after leptin infusion might be mediated by a reduction in ER stress.
Our findings suggest that leptin enhances the effect of central
insulin on hepatic glucose metabolism. Leptin increases hepatic
GLUT2 levels, which could indicate an increased influx of glucose
into the liver (Sole and Srinivasan, 2012). Insulin activates Akt to
phosphorylate GSK3b on Ser9 causing an inhibitory effect (Cross
et al., 1995) and rising glycogen levels. The increase in glycogen
after insulin may act as a “physiological buffer” to maintain glyce-
mia in an adequate range in leptin-treated rats. Moreover, nuclear
localization of Akt in the leptin-treated rats may also potentiate
insulin's effects, as translocation of Akt into the nucleus can exclude
forkhead box O1, a transcription factor for PEPCK (Oh et al., 2013),
thus possibly explaining the lower levels of this gluconeogenic
enzyme.
The results obtained with chronic peripheral leptin adminis-
tration indicate that some of the effects of central leptin infusion
cannot be attributed to hyperleptinemia. Although serum levels
were similar after both treatments, central leptin produced changes
in several hormones related to increased insulin sensitivity and
activated hepatic signaling, whereas the peripheral treatment did
not modify these parameters equally. In addition, the effects of
central leptin infusion on reduction in food intake, bodyweight and
adipose tissue were more potent than peripheral administration, as
previously reported (Suzuki et al., 2010; Penn et al., 2006). Centralleptin administration was also more potent in modulating hepatic
insulin signaling. Finally, it has been reported that the effects of
peripheral or central administration on hepatic leptin signaling
gene expression and metabolism differs (Sharma et al., 2010) and
the leptin-mediated increase in insulin sensitivity seems not to be
due to changes in inflammatory markers after peripheral admin-
istration (Cummings et al., 2011).
Several caveats should be taken into consideration when eval-
uating these results. First, a rise in glycemia after central insulin
infusion is controversial. Although most reports indicate that cen-
tral insulin decreases or has no effect on glycemia, there are studies
demonstrating an increase in glycemia (Ajaya and Haranath, 1982;
Yavropoulou et al., 2009; Burgos-Ramos et al., 2011). This effect
could be related to the role of the autonomous system in con-
ducting brain actions of insulin to the periphery contributing to the
central anorexigenic effects of insulin (Xu et al., 2005). Likewise, the
beneficial action of central leptin infusion on the activation of he-
patic insulin signaling may involve a vagal mechanism. In this re-
gard, leptin increases sympathetic outflow independently of
feeding and regulates serum metabolites by affecting hepatic pro-
cesses (Miyamoto et al., 2012) and controls insulin secretion,
improving glucose tolerance through sympathetic nerve activation
(Park et al., 2010). Nevertheless, these mechanisms are not totally
clear. Hepatic vagal and non-vagal mechanisms on improvement of
peripheral insulin sensitivity after central leptin infusion have been
reported to occur simultaneously (Li et al., 2011) and leptin mod-
ulates hepatic glucose fluxes through central melanocortin-
dependent and independent pathways in order to inhibit gluco-
neogenesis (Gutierrez-Juarez et al., 2004). In addition, the response
of leptin reported here may be considered pharmacological,
although similar dosages exert effects on food intake and energy
homeostasis (Friedman and Halaas, 1998) and reproduce physio-
logical effects (Hidaka et al., 2002; Sahu, 2008). Finally, the
reduction in STAT3 activation in the liver in response to leptin may
be unexpected and related to previous reported effects of this
treatment. In this regard, although icv leptin during the same
period reduced weight gain, the difference in weight gain during
the last days was not significant, suggesting that some animals may
be developing resistant to the treatment (García-Caceres et al.,
2011). Thus, it is possible that there is a reduction in leptin sensi-
tivity in response to the chronic treatment, although this requires
further investigation. In addition, icv leptin activates hepatic
outflow and requires PI3K, but not STAT3 (Tanida et al., 2015).
Moreover, it has been shown that hepatic inhibition of the leptin
signaling pathway improves insulin response (Kim et al., 2008;
Huynh et al., 2010; Li et al., 2014).5. Conclusions
As summarized in Fig. 10, our results suggest that leptin is
involved in the regulation of glycemia through modulation of the
central and hepatic response to central insulin. Our results indicate
a possible important role of the decreased association of SOCS3 to
the insulin receptor in response to leptin, which modulates the
response to an increase in insulin. In leptin treated animals the
hepatic response to central insulin is modified, with key molecules
involved in the hepatic uptake of glucose for glycogen synthesis
being increased and reducing gluconeogenesis. These findings
suggest that pharmacological intervention of leptin and insulin
signaling may be a strategy for controlling glycemia.Disclosure statement
The authors have nothing to disclose.
Fig. 10. Model for the activation of insulin signaling and regulation of glycemia in leptin-infused rats after central insulin administration. Leptin activates hypothalamic insulin
signaling in response to a rise in brain insulin availability that in turn augments circulating a-MSH levels. The increase in serum leptin concentrations, due to central infusion and
augment of its mRNA levels in fat as well, and the increase in hepatic IL-4 could activate hepatic insulin signaling, resulting in an upsurge in GSK3b phosphorylation in Serine 9 with
a subsequent augment of glycogen levels in leptin-treated rats. In addition, lower SOCS3 levels in leptin-treated rats after central insulin infusion may be related with higher insulin
signaling in the liver. After reduction in fat pads in leptin-infused rats, synthesis of proinflammatory interleukins may be diminished, thus also potentiating insulin signaling. On the
other hand, the increase in serum a-MSH and reduction in glucagon could inhibit gluconeogenesis, whereas the augment in GLUT2 would result in glucose uptake for glycogen
synthesis. Thus, the reduction in PEPCK levels and the augment in hepatic glycogen concentrations could be related to a better control of glycemia after insulin administration to
leptin-treated rats. Solid lines represent findings reported here and dashed arrow symbolizes previous described results. a-MSH, a-melanocyte stimulating hormone; Akt, protein
kinase B; GLUT2, glucose transporter 2; GSK3b, glycogen synthase kinase-3b; IL-4, interleukin-4; IR, insulin receptor, IRS1, IR substrate-1; p, phosphorylated; PEPCK, phospho-
enolpyruvate carboxykinase; SOCS3, suppressor of cytokine signaling 3; STAT3, signal transducer and activator of transcription factor 3; T3, triiodothyronine.
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